Aravive Inc (NASDAQ:ARAV) – Equities researchers at Wedbush cut their Q3 2019 earnings per share (EPS) estimates for shares of Aravive in a research note issued to investors on Thursday, August 8th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.61) per share for the quarter, down from their previous forecast of ($0.53). Wedbush also issued estimates for Aravive’s Q4 2019 earnings at ($0.46) EPS, FY2019 earnings at ($1.75) EPS, Q1 2020 earnings at ($0.49) EPS, Q2 2020 earnings at ($0.54) EPS, Q3 2020 earnings at ($0.59) EPS, Q4 2020 earnings at ($0.47) EPS, FY2020 earnings at ($2.09) EPS, FY2021 earnings at ($1.95) EPS, FY2022 earnings at ($2.65) EPS and FY2023 earnings at ($3.69) EPS.
Aravive (NASDAQ:ARAV) last issued its earnings results on Wednesday, August 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.27. The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $1.00 million.
Other equities research analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Aravive from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. ValuEngine downgraded shares of Aravive from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Piper Jaffray Companies assumed coverage on shares of Aravive in a research report on Monday, May 13th. They set an “overweight” rating and a $10.00 price objective for the company.
Shares of NASDAQ:ARAV opened at $6.21 on Monday. Aravive has a 52-week low of $3.07 and a 52-week high of $12.00. The firm has a market cap of $72.64 million, a P/E ratio of -0.58 and a beta of 2.23. The firm has a 50-day moving average price of $5.92. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.28 and a quick ratio of 11.28.
A number of hedge funds have recently modified their holdings of ARAV. BlackRock Inc. bought a new stake in shares of Aravive in the 4th quarter valued at $621,000. Northern Trust Corp bought a new stake in shares of Aravive in the 4th quarter valued at $54,000. Dimensional Fund Advisors LP bought a new position in Aravive during the 4th quarter worth about $484,000. Geode Capital Management LLC bought a new position in Aravive during the 4th quarter worth about $105,000. Finally, Two Sigma Investments LP bought a new position in Aravive during the 4th quarter worth about $124,000. Hedge funds and other institutional investors own 27.57% of the company’s stock.
Aravive Company Profile
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Read More: What is a good dividend yield?
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.